Adaptive clinical trial designs allow changes to an on-going trial based on early examinations of the data. These designs are increasing in popularity, but it is currently unclear what impact they have on health economic analyses that aim to maximise the health gained for money spent. Additionally, opportunities are potentially being missed to incorporate health economic considerations into the design and analysis of adaptive trials.
In this presentation Laura Flight, Scientific Adviser in the Science Policy and Research team at the National Institute for Health and Care Excellence (NICE), UK will provide an overview of the current use of health economics in the design and analysis of adaptive clinical trials, including the potential opportunities and barriers to this approach as highlighted by a range of stakeholders. She will describe how existing theory can be extended to the health economic context to 1) maintain an accurate economic evaluation following an adaptive trial and 2) incorporate value of information analysis at the design stage and during an adaptive design.
Who can attend:
This webinar is open to ACTA Health Economist (HEAT) SIG members and economists within member centres. If you would like information on becoming a member of the HEAT SIG please contact Michael Mihatsch at michael.mihatsch@clinicaltrialsalliance.org.au
About the presenter:
Laura Flight is a Scientific Adviser in the Science Policy and Research team at the National Institute for Health and Care Excellence (NICE), UK. Previously she worked as a Research Fellow in Health Economics and Statistics at the School of Health and Related Research (ScHARR), University of Sheffield. Laura’s methodological research to date has focussed on innovative approaches to the design and conduct of clinical trials with an emphasis on how novel statistical methods can be applied in practice.
Latest Resources
-
-
Approaches to prioritising research
for clinical trial networks: a scoping review -
HEAT Webinar Recording- Economic Evaluation Alongside Adaptive Trials
-
ACTA 2021-2022 Annual Report
-
Effective strategies to manage data integrity risks webinar
-
The Data Lifecycle: Ethical use of data webinar
-
Transparency in data analyses webinar
-
Economic evaluation alongside cluster trial – webinar recording
-
Development of the Consumer Involvement and Engagement Toolkit
-
Activities supporting the growth of Clinical Trial Networks in Australia
-
Strengthening the capacity, efficiency and effectiveness of Clinical Trials Networks: Activity Overview 2017–2021
-
ACTA 2020-2021 Annual Report
-
ACTA Whistleblower Policy
-
MEDIA RELEASE: ACTA appoints Prof Steve Webb as its new Chair and Ian Wilson as Additional Independent Director
-
Official Opening of the 2020 ACTA Summit: Minister’s Address
-
ACTA Year in Review: Financial Year 2019-2020
-
Statistical Analysis Plan (SAP)
-
ACTA Board Charter
-
ACTA Constitution
-
ACTA Trial of the Year Award 2020 guidelines and nomination forms
-
ACTA Year in Review: Financial Year 2018-2019
-
ACTA Resources Brochure
-
ACTA activity work plan 2019 – 2020
-
Report on the activities and achievements of clinical trials networks in Australia 2004 – 2014
-
What a trialist should know about implementation to practice
-
Submission to MRFF Consultation
-
Submission to Medical Research Future Fund Priority Consultation
-
Medical Research Future Fund – clinical trial funding set to deliver significant benefits to Australian patients and the economy
-
ACTA Advisory Council minutes July 2017
-
Economic evaluation of investigator-initiated clinical trials conducted by networks
-
Economic evaluation of investigator-initiated clinical trials conducted by networks – Appendix: Individual trial-level results
-
Open letter to the Hon Greg Hunt MP following announcement of MRFF funding for ACTA and clinical trials
-
How can clinical trials networks drive better translation of evidence into better quality care?
-
The Global Perspective: Measuring the impact of Australian-led trials & registries internationally
-
ACTA Summit 2016 – Opening address
-
ACTA Submission to the NHMRC Public Consultation on revisions to sections 3 & 5 of the National Statement
Latest Events
-
Sector consultations – online discussion with ACTA
-
2022 ACTA ASM including the Australian Registry ASM
-
Improving clinical trial recruitment through innovative technologies
-
Clinical Quality Registries (CQR) SIG member webinar – Oct 2022
-
ACTA CEO update – October 2022
-
ACTA STInG 3 part webinar series on Data Transparency (DT)
-
ACTA CEO update – August 2022
-
Economic evaluation alongside cluster trial webinar
-
Clinical Trials (CT) Socials
-
Clinical Trials 2022: National Tribute and Awards
-
Clinical Trials 2021: National Tribute and Award Ceremony
-
Clinical Trials 2020: National Tribute and Award Ceremony
-
ACTA Summit and Clinical Trials 2020 National Tribute and Award Ceremony
-
ACTA Annual General Meeting
-
ACTA Advisory Council
-
ACTA International Clinical Trials Conference 2 – 5 October 2019